During the corresponding time, Intelgenx Technologies Corp recorded a revenue increase by 7.41 % year on year, sequentially revenue fell by -58.27 %. While revenue at the Intelgenx Technologies Corp 's corporate clients
Intelgenx Technologies's Comment on Sales, Marketing and Customers
The company operates in the pharmaceutical and veterinary markets through three primary delivery platform technologies: VersaFilm™, VetaFilm™, and DisinteQ™. VersaFilm™ is designed for human patients requiring rapid onset of action and enhanced bioavailability, addressing conditions such as migraine, opioid dependence, chronic pain, motion sickness, erectile dysfunction, and nausea, as well as serving pediatric, geriatric, and patients with swallowing difficulties. VetaFilm™ targets companion animals, emphasizing pet compliance through flavors appealing to pets and rapid adhesion to the oral mucosa. DisinteQ™ provides controlled drug release within the oral cavity. The company's product portfolio includes both generic and branded products, predominantly utilizing VersaFilm™ technology. A key product is a Rizatriptan oral film developed with VersaFilm™, submitted to the FDA as a bioequivalent alternative to Maxalt-MLT® orally disintegrating tablets.
Intelgenx Technologies’s Comment on Sales, Marketing and Customers
The company operates in the pharmaceutical and veterinary markets through three primary delivery platform technologies: VersaFilm™, VetaFilm™, and DisinteQ™. VersaFilm™ is designed for human patients requiring rapid onset of action and enhanced bioavailability, addressing conditions such as migraine, opioid dependence, chronic pain, motion sickness, erectile dysfunction, and nausea, as well as serving pediatric, geriatric, and patients with swallowing difficulties. VetaFilm™ targets companion animals, emphasizing pet compliance through flavors appealing to pets and rapid adhesion to the oral mucosa. DisinteQ™ provides controlled drug release within the oral cavity. The company's product portfolio includes both generic and branded products, predominantly utilizing VersaFilm™ technology. A key product is a Rizatriptan oral film developed with VersaFilm™, submitted to the FDA as a bioequivalent alternative to Maxalt-MLT® orally disintegrating tablets.
Sources:
Intelgenx Technologies Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Intelgenx Technologies Corp’s corporate clients.
For your research, we’ve provided 9 tables on Intelgenx Technologies Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
